These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 25928015)

  • 1. FL118, a novel camptothecin derivative, is insensitive to ABCG2 expression and shows improved efficacy in comparison with irinotecan in colon and lung cancer models with ABCG2-induced resistance.
    Westover D; Ling X; Lam H; Welch J; Jin C; Gongora C; Del Rio M; Wani M; Li F
    Mol Cancer; 2015 Apr; 14():92. PubMed ID: 25928015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FL118, a novel camptothecin analogue, overcomes irinotecan and topotecan resistance in human tumor xenograft models.
    Ling X; Liu X; Zhong K; Smith N; Prey J; Li F
    Am J Transl Res; 2015; 7(10):1765-81. PubMed ID: 26692923
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reversal of breast cancer resistance protein (BCRP/ABCG2)-mediated drug resistance by novobiocin, a coumermycin antibiotic.
    Shiozawa K; Oka M; Soda H; Yoshikawa M; Ikegami Y; Tsurutani J; Nakatomi K; Nakamura Y; Doi S; Kitazaki T; Mizuta Y; Murase K; Yoshida H; Ross DD; Kohno S
    Int J Cancer; 2004 Jan; 108(1):146-51. PubMed ID: 14618629
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance.
    Nakamura Y; Oka M; Soda H; Shiozawa K; Yoshikawa M; Itoh A; Ikegami Y; Tsurutani J; Nakatomi K; Kitazaki T; Doi S; Yoshida H; Kohno S
    Cancer Res; 2005 Feb; 65(4):1541-6. PubMed ID: 15735043
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ABCG2 overexpression in colon cancer cells resistant to SN38 and in irinotecan-treated metastases.
    Candeil L; Gourdier I; Peyron D; Vezzio N; Copois V; Bibeau F; Orsetti B; Scheffer GL; Ychou M; Khan QA; Pommier Y; Pau B; Martineau P; Del Rio M
    Int J Cancer; 2004 May; 109(6):848-54. PubMed ID: 15027118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel small molecule FL118 that selectively inhibits survivin, Mcl-1, XIAP and cIAP2 in a p53-independent manner, shows superior antitumor activity.
    Ling X; Cao S; Cheng Q; Keefe JT; Rustum YM; Li F
    PLoS One; 2012; 7(9):e45571. PubMed ID: 23029106
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel camptothecin analogues that circumvent ABCG2-associated drug resistance in human tumor cells.
    Yoshikawa M; Ikegami Y; Hayasaka S; Ishii K; Ito A; Sano K; Suzuki T; Togawa T; Yoshida H; Soda H; Oka M; Kohno S; Sawada S; Ishikawa T; Tanabe S
    Int J Cancer; 2004 Jul; 110(6):921-7. PubMed ID: 15170677
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel acrylonitrile derivatives, YHO-13177 and YHO-13351, reverse BCRP/ABCG2-mediated drug resistance in vitro and in vivo.
    Yamazaki R; Nishiyama Y; Furuta T; Hatano H; Igarashi Y; Asakawa N; Kodaira H; Takahashi H; Aiyama R; Matsuzaki T; Yagi N; Sugimoto Y
    Mol Cancer Ther; 2011 Jul; 10(7):1252-63. PubMed ID: 21566063
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An ABCG2 non-substrate anticancer agent FL118 targets drug-resistant cancer stem-like cells and overcomes treatment resistance of human pancreatic cancer.
    Ling X; Wu W; Fan C; Xu C; Liao J; Rich LJ; Huang RY; Repasky EA; Wang X; Li F
    J Exp Clin Cancer Res; 2018 Oct; 37(1):240. PubMed ID: 30285798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gefitinib enhances the antitumor activity and oral bioavailability of irinotecan in mice.
    Stewart CF; Leggas M; Schuetz JD; Panetta JC; Cheshire PJ; Peterson J; Daw N; Jenkins JJ; Gilbertson R; Germain GS; Harwood FC; Houghton PJ
    Cancer Res; 2004 Oct; 64(20):7491-9. PubMed ID: 15492275
    [TBL] [Abstract][Full Text] [Related]  

  • 11. C421 allele-specific ABCG2 gene amplification confers resistance to the antitumor triazoloacridone C-1305 in human lung cancer cells.
    Bram EE; Ifergan I; Grimberg M; Lemke K; Skladanowski A; Assaraf YG
    Biochem Pharmacol; 2007 Jun; 74(1):41-53. PubMed ID: 17481587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular modeling of new camptothecin analogues to circumvent ABCG2-mediated drug resistance in cancer.
    Nakagawa H; Saito H; Ikegami Y; Aida-Hyugaji S; Sawada S; Ishikawa T
    Cancer Lett; 2006 Mar; 234(1):81-9. PubMed ID: 16309825
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitative evaluation of the combination between cytotoxic drug and efflux transporter inhibitors based on a tumour growth inhibition model.
    Sostelly A; Payen L; Guitton J; Di Pietro A; Falson P; Honorat M; Boumendjel A; Gèze A; Freyer G; Tod M
    Fundam Clin Pharmacol; 2014 Apr; 28(2):161-9. PubMed ID: 23384250
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ABCG2 inhibitor YHO-13351 sensitizes cancer stem/initiating-like side population cells to irinotecan.
    Shishido Y; Ueno S; Yamazaki R; Nagaoka M; Matsuzaki T
    Anticancer Res; 2013 Apr; 33(4):1379-86. PubMed ID: 23564776
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The acridone derivative MBLI-87 sensitizes breast cancer resistance protein-expressing xenografts to irinotecan.
    Arnaud O; Boumendjel A; Gèze A; Honorat M; Matera EL; Guitton J; Stein WD; Bates SE; Falson P; Dumontet C; Di Pietro A; Payen L
    Eur J Cancer; 2011 Mar; 47(4):640-8. PubMed ID: 21216589
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vatalanib sensitizes ABCB1 and ABCG2-overexpressing multidrug resistant colon cancer cells to chemotherapy under hypoxia.
    To KK; Poon DC; Wei Y; Wang F; Lin G; Fu LW
    Biochem Pharmacol; 2015 Sep; 97(1):27-37. PubMed ID: 26206183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ABCG2 mediates differential resistance to SN-38 (7-ethyl-10-hydroxycamptothecin) and homocamptothecins.
    Bates SE; Medina-Pérez WY; Kohlhagen G; Antony S; Nadjem T; Robey RW; Pommier Y
    J Pharmacol Exp Ther; 2004 Aug; 310(2):836-42. PubMed ID: 15075385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sorafenib overcomes irinotecan resistance in colorectal cancer by inhibiting the ABCG2 drug-efflux pump.
    Mazard T; Causse A; Simony J; Leconet W; Vezzio-Vie N; Torro A; Jarlier M; Evrard A; Del Rio M; Assenat E; Martineau P; Ychou M; Robert B; Gongora C
    Mol Cancer Ther; 2013 Oct; 12(10):2121-34. PubMed ID: 23960095
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer.
    Han JY; Lim HS; Yoo YK; Shin ES; Park YH; Lee SY; Lee JE; Lee DH; Kim HT; Lee JS
    Cancer; 2007 Jul; 110(1):138-47. PubMed ID: 17534875
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FL118 inhibits viability and induces apoptosis of colorectal cancer cells via inactivating the CIP2A/PP2A axis.
    Lin X; Gao M; Zhang A; Tong J; Zhang X; Su Q; Yang Z; Gao H; Jiang G
    Life Sci; 2019 Dec; 239():117074. PubMed ID: 31751585
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.